greeksoup/ stock research

Omeros Corp.: Q2 FY2026 earnings call

What management said about Q2 FY2026, from the documents filed with the SEC on 12 August 2026: press release. Guidance figures: 1 new, 2 kept. The quarter’s numbers.

Key takeaways

  • YARTEMLEA gross revenue rose 190%: Gross revenue was $32.2 million in the second quarter, up $21.1 million from $11.1 million in the first quarter, per the release. Source
  • Net income fell from first quarter: Net income was $13.2 million, or $0.18 per share, against $56.1 million in the first quarter. Non-GAAP adjusted net income was $1.8 million, or $0.02 per share. Source
  • CHMP adopted negative opinion in June: In June the CHMP of the EMA adopted a negative opinion on the narsoplimab marketing authorization application for TA-TMA. Source
  • Non-cash derivative gains recorded: Second-quarter results included an $11.5 million non-cash gain, and the first quarter a $73.1 million gain, both mostly from marking the 2029 Notes embedded derivative to market. Source
  • 2029 Notes repurchased for $60.2 million: Repurchases of $30.5 million principal were completed in July for $60.2 million plus accrued interest. About $40.3 million of 2029 Notes remains. The company eliminated $8.6 million of future interest. Source
  • Conversion shares cut to 6.5 million: Shares issuable on conversion of the 2029 Notes fell from about 11.4 million to 6.5 million, at a weighted average repurchase cost of $12.21 per share. Source

“YARTEMLEA is saving lives and, with FDA approval, is now broadly accessible in the U.S.”

Gregory A. Demopulos, M.D., Omeros’ Chairman and Chief Executive Officer

Guidance

AreaPeriodFigureAgainst last quarter
OMS527 clinical trial Sourceyear-end 2026start enrollment in the inpatient clinical trial by year-end 2026Kept
OMS805 Phase 1b trial Sourcelate 2027begin in late 2027New
YARTEMLEA NTAP reimbursement Sourceeffective October 1, 2026effective October 1, 2026Kept

What changed from last quarter

  • New: Europe moved from an expected mid-2026 decision to a negative CHMP opinion in June, and the company requested re-examination. Source
  • New: The company agreed in June to repurchase 2029 Notes in privately negotiated transactions, completed in July. Source
  • New guidance: A targeted start for the OMS805 first-in-human Phase 1b trial, late 2027, appears in this release. The prior release gave no date. Source
  • Guidance kept: CMS granted NTAP status with an October 1, 2026 effective date, the date the prior release expected. Source
  • New: The list of YARTEMLEA indications under assessment is broader than in the prior release, adding endothelial injury and thrombo-inflammation conditions. Source

Results and growth drivers

  • YARTEMLEA gross revenue rose 190%: Gross revenue was $32.2 million in the second quarter, up $21.1 million from $11.1 million in the first quarter, per the release. Source
  • Net income fell from first quarter: Net income was $13.2 million, or $0.18 per share, against $56.1 million in the first quarter. Non-GAAP adjusted net income was $1.8 million, or $0.02 per share. Source
  • Operating income reached $0.1 million: The company reported operating income of $0.1 million for the second quarter, compared with an operating loss of $17.4 million in the first quarter. Source

YARTEMLEA launch and reimbursement

  • Gross-to-net adjustments held near 11.5%: Gross-to-net adjustments were approximately 11.5% in the second quarter, against about 11.0% in the first quarter. Source
  • NTAP granted, effective October 1: CMS granted New Technology Add-on Payment status for inpatient cases involving YARTEMLEA. A permanent J-code specific to the product became effective July 1, 2026. Source
  • Assessment widened to more indications: The company is assessing YARTEMLEA in additional conditions. The list adds chemotherapy-induced TMA, graft-versus-host disease, and sinusoidal obstruction syndrome beyond earlier listed areas. Source

“Equally gratifying are the consistent reports from transplant physicians nationwide describing responses to YARTEMLEA in their adult and pediatric patients”

Gregory A. Demopulos, M.D., Omeros’ Chairman and Chief Executive Officer

European regulatory review

  • CHMP adopted negative opinion in June: In June the CHMP of the EMA adopted a negative opinion on the narsoplimab marketing authorization application for TA-TMA. Source
  • Re-examination to use expert group: The re-examination includes an Ad Hoc Expert Group of external scientists and clinicians in hematology and stem cell transplantation, who will review the evidence. Source
  • Expanded access continues in Europe: YARTEMLEA remains available to transplant physicians in Europe through an expanded access program, with children with TA-TMA prioritized. Source

Pipeline and programs

  • OMS527 nonclinical study before inpatient trial: OMS527 for cocaine use disorder, funded by NIDA, will run a nonclinical study responding to an FDA request before the inpatient trial. Preclinical work showed no drug-interaction or safety issues. Source
  • OncotoX-AML first-in-human timing set: OMS805 showed efficacy superior to AML standards of care in animal and cell-line studies. IND-enabling studies are underway, and a manufacturing agreement covers drug substance supply. Source
  • Nonhuman primate result restated: The February nonhuman primate study, reported earlier, showed selective reduction of myeloid progenitor cells with no observed safety findings. Source
  • OMS1029 Phase 2 indication being finalized: The company is finalizing the initial indication for a Phase 2 program of OMS1029, a long-acting MASP-2 antibody. Source
  • T-CAT manuscript published June 17: The first peer-reviewed T-CAT paper, on engineered antibodies against bacterial immune evasion, was published in Science Translational Medicine. Source

“Collectively, these programs position Omeros for a broad range of value-driving milestones over the next 18 months.”

Gregory A. Demopulos, M.D., Omeros’ Chairman and Chief Executive Officer

Costs, interest and other items

  • R&D and SG&A near prior quarter: Research and development and SG&A totaled about $27.7 million in the second quarter, against $26.7 million in the first quarter. R&D was $13.8 million and SG&A $13.9 million. Source
  • Interest and other income rose: Interest and other income was $4.6 million, up $3.1 million, mainly from a Novo Nordisk reimbursement for transferring zaltenibart inventory. Source
  • Non-cash derivative gains recorded: Second-quarter results included an $11.5 million non-cash gain, and the first quarter a $73.1 million gain, both mostly from marking the 2029 Notes embedded derivative to market. Source
  • Interest expense rose to $7.6 million: Interest expense, net of remeasurement and other, was $7.6 million, against $5.9 million in the first quarter. The 2029 Notes contributed $3.1 million of it. Source

Capital structure and convertible notes

  • Cash and short-term investments reported: Cash and short-term investments stood at $132.0 million at June 30, 2026, against $135.3 million at March 31, 2026. Source
  • 2029 Notes repurchased for $60.2 million: Repurchases of $30.5 million principal were completed in July for $60.2 million plus accrued interest. About $40.3 million of 2029 Notes remains. The company eliminated $8.6 million of future interest. Source
  • Conversion shares cut to 6.5 million: Shares issuable on conversion of the 2029 Notes fell from about 11.4 million to 6.5 million, at a weighted average repurchase cost of $12.21 per share. Source

Share repurchases and operating cash

  • Q2 buybacks retired about 0.5 million shares: The company retired about 0.5 million shares in the quarter for $5.7 million in aggregate, at an average cost of $11.70 per share. Source
  • Six-month buybacks about 0.8 million shares: For the six months, about 0.8 million shares were retired under the repurchase program, for $9.9 million in aggregate at the same $11.70 average cost. Source
  • Operating cash provided $4.1 million: Company-wide net cash provided by operations was $4.1 million for the three months ended June 30, 2026. Source

Partnership and pipeline scope

  • Novo Nordisk holds zaltenibart rights: Under an asset purchase and licensing agreement, Novo Nordisk acquired global rights to zaltenibart, a MASP-3 inhibitor in clinical development. Source
  • Pipeline spans antibodies, MASP-2 and oncology: The pipeline includes OMS527 for addiction, a growing set of recombinant antibodies against multidrug-resistant organisms, and oncology programs. Source
  • OMS1029 completed Phase 1 trials: OMS1029, the long-acting MASP-2 inhibitor, has completed Phase 1 clinical trials, per the company description. Source

Coming up, as management said on 12 August 2026

  • MASP-2 small-molecule candidate selection: Once one ongoing study completes, the company expects to select a drug development candidate in its MASP-2 small-molecule program. Source
  • EMA re-examination outcome pending: The company believes the evidence supports approval and has requested re-examination. No date for the outcome is given. Source

Figures management reported

FigureReported
YARTEMLEA gross product sales Source$32.2 million, second quarter 2026
YARTEMLEA net product sales Source$28.5 million, second quarter 2026
Gross-to-net adjustments Sourceapproximately 11.5%
Research and development expense Source$13.8 million, three months ended June 30, 2026
Pipeline milestone SourceOMS805 Phase 1b start targeted late 2027
Regulatory decision SourceNegative CHMP opinion on narsoplimab MAA for TA-TMA, June 2026

Risks management discussed

  • Regulatory: The European review of narsoplimab for TA-TMA may not end in approval, as the CHMP adopted a negative opinion and re-examination is pending. Source
  • Financial: Reported net income includes non-cash fair-value changes on the 2029 Notes embedded derivative, which can move GAAP results from one quarter to the next. Source

Earlier plans management reported on

  • On track: Management said the work with Novo Nordisk on zaltenibart remained on track toward Phase 3 trial initiation. Source
  • Not stated: The prior release expected an EMA decision in mid-2026. The June CHMP opinion in this release was negative, and management did not restate the timing.
  • On track: CMS granted NTAP status, with the effective date of October 1, 2026 still ahead, as the prior release expected. Source
  • Met: The permanent J-code specific to YARTEMLEA became effective on the July 1, 2026 date the prior release gave. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.